ライフサイエンスコーパス: LC-MS

1 LC-MS based metabolomics approach revealed that putative

2 LC-MS identified 26 compounds.

3 LC-MS identified 3090 proteoforms, including 1707 unique

4 LC-MS-based profiling of circulating angiotensin peptide

5 LC-MS/MS analyses revealed that the levels of cross-link

6 LC-MS/MS method for confirmation of nitrofuran metabolit

7 LC-MS/MS product ion scans were used to identify and sem

8 chromatography-tandem mass spectrometry (1D LC-MS/MS) workflow (i.e., from sample preparation to HCP

9 The identification output of the 2D LC-MS/MS system is driven by both separation orthogonali

10 on configuration was designed to automate 2D-LC-MS/MS.

11 chromatography-tandem mass spectrometry (2D-LC-MS/MS) method which combines commercially available p

12 t types of bread and bakery products using a LC-MS/MS method, before and after the new European regul

13 r goals in this study were to (i) validate a LC-MS method that assesses HBP flux as UDP-GlcNAc ((13)C

14 s measurement of mAb in major tissues with a LC-MS-based method, where interesting features of mAb ti

15 chidonic acid is the predominant fatty acid, LC-MS analysis identified 2-AG as the main product of LP

16 k paves the road for implementing additional LC-MS methods to modernize testing in commercial QC with

17 d when PE-LC-MS/MS was compared to MA and AE-LC-MS/MS, respectively.

18 njugase (rat serum and chicken pancreas) (AE-LC-MS/MS) was used in the LC-MS/MS methods, each in a si

19 oduce the final quantification results after LC-MS analysis.

20 AhpD variants remained partially active, and LC-MS/MS analyses revealed that the third cysteine, Cys-

21 We used plate growth and Seahorse assays and LC-MS/MS analysis to show that COQ11 deletion rescues re

22 ssed by RNA sequencing, Seahorse assays, and LC-MS/MS.

23 munoaffinity capture, chemical cleavage, and LC-MS/MS.

24 Using immunoblotting, flow cytometry, and LC-MS-based glycolipid and glycan profiling, we found th

25 3-ols) was analyzed using GC-FID, LC-DAD and LC-MS methods, whereas the volatile compound profile was

26 cluding FTIR, UV spectrophotometry, HPLC and LC-MS analysis.

27 ll rely on UV-Visible spectroscopy, HPLC and LC-MS methods.

28 ored spectrophotometrically, and by HPLC and LC-MS respectively, while antioxidant capacity was measu

29 combining oligonucleotide hybridization and LC-MS/MS technologies.

30 e enzyme presented approximately 65 kDa, and LC-MS/MS allowed the identification of a polyurethanase

31 mic analysis using TMT peptide labelling and LC-MS/MS revealed that FloR is a physiological master re

32 eat potential to replace traditional LBA and LC-MS/MS methods.

33 ate measurements) from sheathless CZE-MS and LC-MS resulted in the identification of 1433 proteoforms

34 The use of sheathless CZE-MS and LC-MS with EThcD and 213 nm UVPD provided complementary

35 1)H NMR and mass spectroscopy (FIA-MS/MS and LC-MS/MS) techniques.

36 Innovative chemometric approaches by NMR and LC-MS data fusion (multiblock analysis) and decompositio

37 nholide A and luminaolide B by 1D/2D NMR and LC-MS(2) analysis.

38 ocedure including the sample preparation and LC-MS/MS takes less than 55 min, enabling rapid multiatt

39 elope associated peptidase (CEP) profile and LC-MS/MS analysis of peptides.

40 using Zeiss Zen Black microscopy systems and LC-MS protocols that are standard in many research cores

41 troscopy, and mass spectrometry (ESI-TOF and LC-MS), as well as (17)O solid state NMR (for the (17)O

42 method applied, based on rapid clean-up and LC-MS/MS determination, was previously developed and in-

43 cterizations viz., proton-HNMR, FTIR, UV and LC-MS.

44 Overall, the data generated from antibody LC-MS analyses can provide key information in early phas

45 capabilities comparable to the state-of-art LC-MS but suggest a selectivity for the detection of a d

46 ng liposome-leakage and cytotoxicity assays, LC-MS/MS-based proteomics, and CCF-4 FRET analysis, we o

47 ere, using MS-based FAHFA hydrolysis assays, LC-MS-based lipidomics analyses, and activity-based prot

48 TS platform is not compatible with automated LC-MS systems, which significantly limits sample through

49 ocapture enrichment prior to MIRM-ISCC-based LC-MS/MS analysis.

50 quid chromatography-mass spectrometry-based (LC-MS-based) metabolomics, we profiled more than 1600 mo

51 (LC-MS), exhibiting a high agreement between LC-MS and MALDI-Q-MSI (Pearson correlation r = 0.87).

52 ntermediate during C(alpha)-thioether bridge LC-MS/MS fragmentation.

53 specimens from each rabbit were analyzed by LC MS/MS iTRAQ technology using an Orbitrap Fusion Lumos

54 ed flavonoids, alkamides and fatty acids, by LC-MS analysis.

55 cluding several oxidized ACs was analyzed by LC-MS in plasma and urine samples collected after the 3-

56 were collected at intervals and analyzed by LC-MS.

57 present in each compartment were analyzed by LC-MS.

58 , and the peptidomic profile was assessed by LC-MS/MS.

59 isolated in ~31% yield, and characterized by LC-MS, (1)H and (13)C NMR, and FT-IR methodologies, as w

60 transmethylation reactions were confirmed by LC-MS, nuclear magnetic resonance (NMR), and rationalize

61 e structures of the latter were confirmed by LC-MS.

62 5)N-tracers) in any metabolite detectable by LC-MS/MS and in various biological models (such as mice)

63 84 compounds identified in both genotypes by LC-MS/MS, including phenolic acids, organic acids, flavo

64 he antioxidant activities were identified by LC-MS, including phenolic acids, anthocyanins, stilbenes

65 es and determined their expression levels by LC-MS/MS using both synchronous precursor selection (SPS

66 rative data obtained demonstrate that MAM by LC-MS peptide mapping can, in principle, adequately repl

67 metabolites in the Trp catabolic pathway by LC-MS-MS in the community-based Hordaland Health Study (

68 techolamines, and metanephrines in plasma by LC-MS/MS.

69 Metabolite profiling by LC-MS and GC-MS quantified 124 seed metabolites out of w

70 lycolipids were identified and quantified by LC-MS and MS/MS and their profile statistically analysed

71 low (BMW) in which the same sample is run by LC-MS in both liquid chromatography solvent with (14)NH(

72 oral skeletal proteomes that we sequenced by LC-MS/MS over multiple trials in the best-preserved foss

73 ges, we developed a generic affinity capture LC-MS assay that can be utilized to evaluate the biotran

74 Affinity capture LC-MS of intact ADCs or ADC subfragments has been extens

75 al and Laboratory Standards Institute (CLSI) LC-MS C62-A document and the U.S. Food and Drug Administ

76 ides (HMOs) derived from results of combined LC-MS/MS experiments and comprehensive structural analys

77 Polyphenol composition (LC-MS) and antioxidant capacity (PCL, FRAP) were measure

78 Here, we present a comprehensive LC-MS/MS based approach that allows unequivocal distinct

79 ot be identified or detected by conventional LC-MS analyses without enrichment, demonstrating the uti

80 say sensitivity compared to the conventional LC-MS/MS method.

81 s significantly correlated with conventional LC-MS results.

82 cation that was comparable with conventional LC-MS(/MS).

83 test the performance of a recently developed LC-MS/MS method for quantification of 6 folate forms.

84 ment used and are not the same for different LC-MS systems.

85 ter re-extraction by stable isotope dilution LC-MS/MS analysis.

86 Using stable isotope dilution LC-MS/MS, we detected the formation of 3-bromotyrosine,

87 ed that PCI-IS was an accurate and efficient LC-MS/MS method to simultaneously estimate blood volume

88 signals typically present in untargeted ESI-LC-MS metabolomics data.

89 ere used for the extension of an established LC-MS/MS-based method for the quantitation of several im

90 ty spectrometry (IMS) separation to existing LC-MS workflows for PFAS analysis.

91 n of on-tissue MS/MS and hydrogel extraction LC-MS/MS, peptides from the enamel, dentin, periodontal

92 en compared to those obtained by the fastest LC-MS/MS method previously reported, along with a 15-fol

93 Here, we report on the first LC-MS/MS method for the simultaneous quantification of t

94 This study demonstrates that micro-flow LC-MS/MS is suitable for a broad range of proteomic appl

95 Here we show that micro-flow LC-MS/MS using a 1 x 150 mm column shows excellent repro

96 tography tandem mass spectrometry (nano-flow LC-MS/MS) is the mainstay in proteome research because o

97 However, a major challenge for LC-MS-based methods is that there can be a more than 5 o

98 he chemical compound will be of big help for LC-MS/MS-based omics.

99 ction sensitivity than TFA mobile phases for LC-MS-based characterization of biopharmaceuticals.

100 workup in multiple 96-well filter plates for LC-MS/MS analysis.

101 in the automation of sample preparation for LC-MS analysis, a challenging next step is to fully auto

102 quires a great amount of instrument time for LC-MS data acquisition of individual digested samples, w

103 iscover alternative splicing biomarkers from LC-MS/MS using RNA-Seq.

104 ained data correlated well with results from LC-MS/MS chemical analysis but also revealed unknown PSI

105 The hybridization LC-MS/MS was considered an improved alternative for quan

106 Immunoaffinity (IA) LC-MS/MS pharmacokinetic (PK) assays are widely used in

107 Research Centre (JRC) developed an improved LC-MS/MS analytical method using a pentafluorophenyl col

108 Despite the recent advances in LC-MS/MS methodologies, the profiling of site-specific g

109 Improvements in LC-MS/MS methods and technology have enabled the identif

110 erated during the ionization of molecules in LC-MS.

111 drophobicity, which can be well separated in LC-MS/MS.

112 idge the inconsistencies between incongruent LC-MS metabolomics datasets of the same biological sampl

113 nd correlated with a hydrophilic interaction LC-MS/MS method for measuring plasma metanephrines (R(2)

114 Moreover, it is LC-MS compatible and can also be used in combination wit

115 inatorial peptide ligand libraries and iTRAQ-LC-MS/MS.

116 d evaluate separation orthogonality in 3D LC-LC-MS separation space for all systems under investigati

117 Overall, it identified 26% of ~27 000 liver LC-MS features as putative metabolites, of which ~2600 s

118 cGTW applied to two large-scale metabolomics LC-MS datasets identifies many misaligned features and s

119 romatography tandem mass spectrometry (micro-LC-MS/MS) assay for the quantification of endogenous NPY

120 wed by solid-phase extraction prior to micro-LC-MS/MS.

121 s spectrometry multiple reaction monitoring (LC-MS/MS MRM) assay.

122 erate the active drug, and quantified by MRM LC-MS/MS.

123 mple preparation, quantitative LC-tandem MS (LC-MS/MS) analysis, and data processing methods are prov

124 o individual metabolites generating multiple LC-MS peaks arising from isotopes, adducts, and fragment

125 graphitic carbon (PGC) columns for nanoflow LC-MS/MS analyses of native glycans released from glycop

126 ensitivity, and use of capillary or nanoflow LC-MS.

127 Multivariate statistical analysis of LC-MS data was used to identify key outlier features in

128 In the past decade, the field of LC-MS-based metabolomics has transformed from an obscure

129 oportion of the complexity and redundancy of LC-MS metabolomics data comes from adduct formation.

130 Based on LC-MS/MS-derived sequences of natural Rhi o 2, the full-

131 from maize and subsequent quantification on LC-MS/MS.

132 Herein, we develop an online LC-MS/MS method for rapid analysis of reduced ADCs witho

133 a antibody drug conjugate subunits in online LC-MS experiments.

134 For the optimized LC-MS/MS method described herein, we applied the guideli

135 fields, which utilize high-resolution GC- or LC-MS techniques.

136 sensitivity drop in traditional ion-pairing LC-MS/MS was for the first time overcome by the introduc

137 s thaliana) for deconjugation of folates (PE-LC-MS/MS), or animal-origin deconjugase (rat serum and c

138 The PE-LC-MS/MS provides fast quantification of various folate

139 wer and 25% higher results was found when PE-LC-MS/MS was compared to MA and AE-LC-MS/MS, respectivel

140 ested cells using flow cytometry and perform LC-MS/MS to identify chromosome-bound proteins.

141 transcriptomics, and ultra-high-performance LC-MS/MS- and GC/MS-based metabolomics, we found that, a

142 Ultra-performance LC-MS was used to measure 18,640 adipose-derived feature

143 , and alpha-1 acid glycoprotein (AGP) by PGC-LC-MS.

144 human AGP revealed the potential use of PGC-LC-MS for extensive glycoprotein analysis for biomarker

145 To promote the PGC-LC-MS/MS-based method for glycome-wide applications, we

146 rmance, we analyzed data from reversed phase LC-MS and hydrophilic interaction chromatography (HILIC)

147 re generated empirically from reversed-phase LC-MS studies.

148 by a factor of 4-30 compared with a previous LC-MS/MS method for measuring plasma metanephrines in ou

149 ational modifications employing a proteomics LC-MS/MS platform.

150 gluten peptides was defined by quantitative LC-MS/MS; none were detected in the gastric phase, but r

151 sequently analysed by SDS-PAGE, quantitative LC-MS/MS, untargeted LC-MS/MS and ELISA.

152 yphenol, during storage through quantitative LC-MS/MS-based analysis.

153 n of the PhotoPPI workflow with quantitative LC-MS/MS enabled unbiased interaction mapping for the re

154 not observed in other conventional flow rate LC-MS strategies.

155 entified and confirmed by intact and reduced LC-MS of isolated forms.

156 indings indicate that sensitive and reliable LC-MS/MS methods can be developed for the targeted detec

157 eveloped for the analysis of high-resolution LC-MS data for the purposes of metabolomics, but potenti

158 Untargeted high-resolution LC-MS metabolomic analysis of the extracted filtrates an

159 bing the implementation of a high-resolution LC-MS method in commercial QC laboratories for product r

160 ounds, were detected through high-resolution LC-MS/MS, among which were biomarkers of anammox bacteri

161 affinity chromatography, and high-resolution LC-MS/MS, and we designate it LPHAMS.

162 Here, we describe a sensitive and robust LC-MS/MS assay to quantify clinical protein biomarkers i

163 Previously we have built large-scale LC-MS/MS approaches that can be routinely used for measu

164 tion of untargeted high-resolution full-scan LC-MS metabolomics data remains challenging due to indiv

165 Combining protein and RNA data by searching LC-MS/MS data against a customized protein database from

166 sample preparation, an ultra-fast 84-second LC-MS method, and barcoded nanopore sequencing to rapidl

167 th immunohistochemistry and highly sensitive LC-MS.

168 ysed by HPLC, combined with highly sensitive LC-MS/MS, MALDI-TOF-MS, and exoglycosidase treatments.

169 newly developed, faster, and more sensitive LC-MS/MS method to distinguish different plant-based and

170 by at least 15 V were tested within a single LC-MS run using the FAIMS interface.

171 e.g., PTMs) for multiple samples in a single LC-MS run.

172 g immobilized aspergillopepsin I in a single LC-MS/MS analysis.

173 in complete sequence coverage from a single LC-MS/MS analysis.

174 lysis of many biological samples in a single LC-MS/MS experiment.

175 its site-specific glycosylation in a single LC-MS/MS run and simultaneously determined the donor all

176 he oxidation products quantified in a single LC-MS/MS run.

177 The SPE-LC-MS/MS method was validated in terms of limit of detec

178 uid chromatography-tandem mass spectrometry (LC-MS(2)) is challenging because of the difficulties in

179 uid chromatography tandem mass spectrometry (LC-MS(2)) methods are increasingly being used in conjunc

180 Liquid chromatography-mass spectrometry (LC-MS) affords a highly promising solution for absolute

181 ect liquid chromatography-mass spectrometry (LC-MS) analysis.

182 chromatography coupled to mass spectrometry (LC-MS) approach described in this protocol, samples in M

183 by liquid chromatography-mass spectrometry (LC-MS) at PND 22 or at 7 weeks of age.

184 s a liquid chromatography-mass spectrometry (LC-MS) based quantification platform with high sensitivi

185 raw liquid chromatography-mass spectrometry (LC-MS) data.

186 Liquid chromatography-mass spectrometry (LC-MS) delivers sensitive peptide analysis for proteomic

187 ith liquid chromatography-mass spectrometry (LC-MS) has become an essential analytical technique to q

188 Liquid chromatography-mass spectrometry (LC-MS) has been widely used throughout biotherapeutic de

189 chromatography coupled to mass spectrometry (LC-MS) is a powerful tool for characterization of ADCs.

190 Liquid chromatography-mass spectrometry (LC-MS) is a standard method for proteomics and metabolom

191 chromatography coupled to mass spectrometry (LC-MS) is emerging as a powerful tool that can provide b

192 ced liquid chromatography-mass spectrometry (LC-MS) methods with high sensitivity, accuracy and throu

193 Liquid chromatography-mass spectrometry (LC-MS) results found hallucinogenic alkaloids scopolamin

194 n a liquid chromatography-mass spectrometry (LC-MS) timescale and improve mean sequence coverage dram

195 id chromatography-coupled mass spectrometry (LC-MS) were significantly heritable under the classical

196 by liquid chromatography-mass spectrometry (LC-MS), exhibiting a high agreement between LC-MS and MA

197 romatography coupled with mass spectrometry (LC-MS), has been a powerful technique for studies of pro

198 iquid chromatography with mass spectrometry (LC-MS), which could miss detection or becomes less quant

199 and liquid chromatography-mass spectrometry (LC-MS), which despite producing more reliable results of

200 in liquid chromatography-mass spectrometry (LC-MS)-based biopharmaceutical characterization to enhan

201 ing liquid chromatography-mass spectrometry (LC-MS)-based method, has received increased attention fo

202 Liquid chromatography-mass spectrometry (LC-MS)-based proteomics approaches have been widely used

203 ography coupled to tandem mass spectrometry (LC-MS).

204 uid chromatography-tandem mass spectrometry (LC-MS/MS) analyses on brain homogenates of our newly gen

205 uid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of ethanolic seed crude extract and f

206 uid chromatography-tandem mass spectrometry (LC-MS/MS) and deduced fractional excretion using reporte

207 uid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid chromatography-multiple reaction mo

208 uid chromatography-tandem mass spectrometry (LC-MS/MS) assays were developed to measure arylsulfatase

209 uid chromatography-tandem mass spectrometry (LC-MS/MS) at atmospheric concentrations up to 50 +/- 20

210 matography coupled tandem mass spectrometry (LC-MS/MS) based metabolic profiling were utilized to dis

211 uid chromatography-tandem mass spectrometry (LC-MS/MS) enables the simultaneous quantification of num

212 uid chromatography-tandem mass spectrometry (LC-MS/MS) for clinical applications is still very challe

213 uid chromatography-tandem mass spectrometry (LC-MS/MS) has become the gold-standard technique to stud

214 uid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed and validated for the simul

215 uid chromatography tandem mass spectrometry (LC-MS/MS) highly useful in MFA due to its high sensitivi

216 uid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of vitamins D3 and D

217 uid chromatography-tandem mass spectrometry (LC-MS/MS) method to quantify 14 antiepileptic drugs (AED

218 uid chromatography tandem-mass spectrometry (LC-MS/MS) method.

219 uid chromatography-tandem mass spectrometry (LC-MS/MS) method.

220 uid chromatography-tandem mass spectrometry (LC-MS/MS) methods, an alternative bioanalytical method w

221 ith Liquid chromatography-mass spectrometry (LC-MS/MS) proteomics data and The Cancer Genome Atlas (T

222 uid chromatography-tandem mass spectrometry (LC-MS/MS) providing information on the level of individu

223 uid chromatography-tandem mass spectrometry (LC-MS/MS) remains a significant challenge because of the

224 uid chromatography-tandem mass spectrometry (LC-MS/MS) remains an analytical challenge in large-scale

225 aphy, coupled with tandem mass spectrometry (LC-MS/MS) revealed that luteolin derivative compounds co

226 uid chromatography-tandem mass spectrometry (LC-MS/MS) to detect "twin ions" of peptides that were co

227 uid chromatography-tandem mass spectrometry (LC-MS/MS) to measure and compare PFAS levels between fir

228 uid chromatography-tandem mass spectrometry (LC-MS/MS) together with internal standards.

229 uid chromatography-tandem mass spectrometry (LC-MS/MS) using both positive and negative-mode multiple

230 uid chromatography tandem mass spectrometry (LC-MS/MS) using ten-plex tandem mass tag (TMT) labeling.

231 uid chromatography-tandem mass spectrometry (LC-MS/MS) was used to confirm these results.

232 uid chromatography-tandem mass spectrometry (LC-MS/MS) with the aid of design of experiments (DOE) ap

233 uid chromatography tandem mass spectrometry (LC-MS/MS) workflow to discover novel biomarkers.

234 matography coupled tandem mass spectrometry (LC-MS/MS), have shown tremendous power for the parallel

235 ing liquid chromatography-mass spectrometry (LC-MS/MS).

236 uid chromatography-tandem mass spectrometry (LC-MS/MS).

237 chromatography and tandem mass spectrometry (LC-MS/MS).

238 romatography coupled with mass spectroscopy (LC-MS/MS), we detected 20 steroids within unfertilized e

239 , and accuracy while both CBS-MS/MS and SPME-LC-MS/MS methods achieved limits of quantitation below t

240 ter assay was compared to the gold standard (LC-MS/MS), showing a good correlation between both metho

241 In this study, LC-MS/MS shotgun proteomics was used to identify changes

242 Here antibody subunit LC-MS is utilized for evaluation of two classes of compl

243 , high-throughput, and GMP compliant subunit LC-MS method for monitoring antibody oxidation for comme

244 are collectively presented using the subunit LC-MS approach for the two molecules, and the methods sh

245 The LC-MS analysis indicated that the beta-Lactoglobulin was

246 The LC-MS/MS data were processed by a blended data analytics

247 bility phenolic compounds as resulted by the LC-MS/MS validated method.

248 tines and conjugated acylcarnitines from the LC-MS/MS analysis of six NIST urine reference materials.

249 cken pancreas) (AE-LC-MS/MS) was used in the LC-MS/MS methods, each in a single enzymatic step.

250 Linking the LC-MS analysis of this modified pigment to a naturally p

251 The steps of the LC-MS/MS assay are sufficiently simple and rapid to be u

252 substrate-interacting residue, based on the LC-MS/MS data and available structural models of SrtB-su

253 rized and simultaneously correlated with the LC-MS/MS analysis of RNA modifications within the same s

254 Through LC-MS/MS analysis, we discover that majority of miR-21-5

255 High-throughput LC-MS identified Arabidopsis metabolites.

256 ted a sensitive, robust, and high-throughput LC-MS/MS method to quantify vitamins D3 and D2 in serum.

257 SDS-PAGE coupled to LC-MS analysis of sand fly saliva, before and after enzy

258 automated sample injection from nanowells to LC-MS systems.

259 in situ concentration and digestion prior to LC-MS analysis.

260 and filtration of the final extract prior to LC-MS/MS analysis.

261 ominant polyphenols detected with Triple-TOF-LC-MS/MS.

262 agenesis, biochemical and biophysical tools, LC-MS/MS, and crystallographic analyses, we identified k

263 des novel information to support traditional LC-MS PFAS analyses and will greatly benefit the evaluat

264 oducts, meat, and offal were analyzed by two LC-MS/MS methods and a microbiological assay (MA).

265 to-noise ratios, and detection limits in ULF LC-MS-based measurements by significantly reducing chemi

266 nal nanoESI interface used with the same ULF LC-MS setup.

267 Ultrasensitive LC-MS analysis was achieved using the Orbitrap Eclipse T

268 SDS-PAGE, quantitative LC-MS/MS, untargeted LC-MS/MS and ELISA.

269 commercial kratom products using untargeted LC-MS metabolomics, revealing two distinct chemotypes th

270 nted into sets of b- and y-ion clusters upon LC-MS/MS, which convey not only sequence information but

271 We used LC-MS to quantify SCFA concentrations in fasting serum,

272 MYC in supporting cell growth, here we used LC-MS-based metabolomics to examine the metabolome of MY

273 tinctive peptides, which were analyzed using LC-MS/MS and the SpirPep web-based tool.

274 epoint within cow across day, analyzed using LC-MS/MS techniques, and analyzed for variations across

275 and six folate vitamers were analyzed using LC-MS/MS.

276 n the determination of their free form using LC-MS/MS.

277 Here, using LC-MS-purified BMAA and several biochemical assays, we s

278 fic peptide biomarkers were identified using LC-MS/MS.

279 lts across three litters were measured using LC-MS/MS.

280 Multiplexed AED measurements using LC-MS/MS and LC-DTIM-MS have the potential to enable bet

281 rgeting 26 non-enzymatic modifications using LC-MS.

282 The interest of using LC-MS/MS as a method for detection of allergens in food

283 posed offspring at various time points using LC-MS/MS.

284 AA) and other hormones were quantified using LC-MS/MS.

285 raction of the water extract of tempeh using LC-MS/MS analysis and database-assisted identification.

286 reened bacterial culture media for TTX using LC-MS/MS and identified TTX-producing bacterial strains

287 by apoA-I or HDL3 in vitro and in vivo Using LC-MS/MS analysis, we analyzed the pattern of apoprotein

288 UV-LC-MS(2) features a gradient run of acetonitrile contain

289 olumn reduction tandem mass spectrometry (UV-LC-MS(2)) coupled with two-stage data analysis and spike

290 24h) on day 28 and week 12 using a validated LC-MS/MS assay.

291 tly differ from those of the cross-validated LC-MS/MS method (55.0 +/- 4.9 pmol/mg).

292 generate features typically found in various LC-MS modalities.

293 teen individual BA species were measured via LC-MS/MS and total BA levels were measured using the Dia

294 -MB-468 and SUM-159PT TNBC cells, along with LC-MS/MS and HPLC metabolomics profiling, we found here

295 of the sequences (Sequence 7) combined with LC-MS/MS identified its molecular target complex, whereo

296 RAS-RAM extract was directly compatible with LC-MS/MS and no further re-extraction, evaporation or cl

297 clean-up using restricted access media with LC-MS/MS.

298 ed sensitivity and selectivity provided with LC-MS, yielded additional site-specific information not

299 f BCA and LA ozonolysis were quantified with LC-MS as well as with the UV-vis assays for quantificati

300 in purified monoclonal antibody samples with LC-MS(2).